Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

21. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events. OBJECTIVES: To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies. SEARCH METHODS: In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO

Cochrane2018

22. Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database 29725886 2018 11 14 2199-1154 5 2 2018 Jun Drugs - real world outcomes Drugs Real World Outcomes Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database. 117-128 10.1007/s40801-018-0134-0 Voluntary reports on adverse events (AEs

Drugs - real world outcomes2018 Full Text: Link to full Text with Trip Pro

23. Effect of Systematic Physician Cross-checking on Reducing Adverse Events in the Emergency Department: The CHARMED Cluster Randomized Trial

Effect of Systematic Physician Cross-checking on Reducing Adverse Events in the Emergency Department: The CHARMED Cluster Randomized Trial 29710111 2018 04 30 2168-6114 2018 Apr 23 JAMA internal medicine JAMA Intern Med Effect of Systematic Physician Cross-checking on Reducing Adverse Events in the Emergency Department: The CHARMED Cluster Randomized Trial. 10.1001/jamainternmed.2018.0607 Emergency departments (ED) are environments that are at high risk for medical errors. Previous studies (...) physician's case to another, followed by the second physician's feedback to the first. Medical error in the ED, defined as an adverse event (either a near miss or a serious adverse event). The primary end point was identified using a 2-level error detection surveillance system, blinded to the strategy allocation. Among the 1680 included patients (mean [SD] age, 57.5 [21.7] years), 144 (8.6%) had an adverse event. There were 54 adverse events among 840 patients (6.4%) in the cross-check group compared

EvidenceUpdates2018

24. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes

Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes 30202800 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related (...) adverse events, and patient-reported outcomes. 314-321 10.1016/j.adro.2018.04.003 Pencil-beam scanning intensity modulated proton therapy (IMPT) may allow for an improvement in the therapeutic ratio compared with conventional techniques of radiation therapy delivery for pancreatic cancer. The purpose of this study was to describe the clinical implementation of IMPT for intact and clinically localized pancreatic cancer, perform a matched dosimetric comparison with volumetric modulated arc therapy (VMAT

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

25. Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events

Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events NIHR DC | Signal - Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Infants anaesthetised without placing a tube in the trachea have fewer adverse breathing events Published on 11 July 2017 Adverse breathing events are about three times more common when using endotracheal tubes than (...) have shown them to have fewer airway-related complications than tubes. This Australian randomised controlled trial supported this, finding an adverse event rate of 53% with endotracheal tubes compared with only 18% with laryngeal mask airways. Conventional anaesthesia teaching advises the use of endotracheal tubes in infants even for relatively minor surgery, to provide a secure airway, but incidents may be more common when placing or removing the tube than a laryngeal mask. Why was this study

NIHR Dissemination Centre2018

26. Benchmarking study helps hospitals improve measurement of adverse events

Benchmarking study helps hospitals improve measurement of adverse events NIHR DC | Signal - Benchmarking study helps hospitals improve measurement of adverse events Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Benchmarking study helps hospitals improve measurement of adverse events Published on 20 June 2017 One in ten inpatients in Welsh hospitals experienced an adverse event of some sort, about half of which were potentially preventable. This is very similar to the rate (...) and to better understand how many events were preventable and the degree of harm. The two-step process found 10.3% of patients had an adverse event, while the tool found 8% adverse events. Hospitals which carried out more surgery had higher rates of adverse events. Use of this trigger tool has since been dropped in Wales and a new “hybrid” system of adverse event identification is being developed. Why was this study needed? Global estimates of rates of adverse events range from about 8% to 12% of inpatient

NIHR Dissemination Centre2018

27. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology | |

American Society of Clinical Oncology Guidelines2018

28. Inhalational versus IV Induction of Anesthesia in Children with a High Risk of Perioperative Respiratory Adverse Events: A Randomized Controlled Trial

Inhalational versus IV Induction of Anesthesia in Children with a High Risk of Perioperative Respiratory Adverse Events: A Randomized Controlled Trial 29498948 2018 03 26 1528-1175 2018 Mar 26 Anesthesiology Anesthesiology Inhalational versus IV Induction of Anesthesia in Children with a High Risk of Perioperative Respiratory Adverse Events: A Randomized Controlled Trial. 10.1097/ALN.0000000000002152 Limited evidence suggests that children have a lower incidence of perioperative respiratory (...) adverse events when intravenous propofol is used compared with inhalational sevoflurane for the anesthesia induction. Limiting these events can improve recovery time as well as decreasing surgery waitlists and healthcare costs. This single center open-label randomized controlled trial assessed the impact of the anesthesia induction technique on the occurrence of perioperative respiratory adverse events in children at high risk of those events. Children (N = 300; 0 to 8 yr) with at least two clinically

EvidenceUpdates2018

30. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. Importance: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain. Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE

JAMA2018 Full Text: Link to full Text with Trip Pro

31. Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis

Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis 29335343 2018 03 02 0315-162X 45 3 2018 Mar The Journal of rheumatology J. Rheumatol. Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis. 320-328 10.3899/jrheum.170418 Oral glucocorticoid (OGC) use for rheumatoid arthritis (RA (...) ) is debated because of the adverse event (AE) profile of OGC. We evaluated the associations between cumulative doses of OGC and potential OGC-related AE, and quantified the associated healthcare expenditures. Using the MarketScan databases, patients ≥ 18 years old who have RA with continuous enrollment from January 1 to December 31, 2012 (baseline), and from January 1 to December 31, 2013 (evaluation period), were identified. Cumulative OGC dose was measured using prescription claims during the baseline

EvidenceUpdates2018

32. Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir February 2018, Volume: 10, Issue: 2, Pages: 6383-6389, DOI: http://dx.doi.org/10.19082/6383 Corresponding author: Assistant Professor Dr. Ahmadnoor Abdi. Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Tel: +98.7633337379, Fax: +98.7633337192, Email: ahmadnoorabdi@gmail.com (...) Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow- up study Hossein Farshidi 1 , Ahmadnoor Abdi 2 , Abdulhussain Madani 3 , Shahram Moshiri 4 , Abolfazl Ghasemi 5 , Ruhollah Hakimian 5 1 M.D., Interventional Cardiologist, Associate Professor of Cardiology, Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 2 M.D. Interventional Cardiologist, Assistant Professor of Cardiology, Cardiovascular Research Center

Electronic physician2018 Full Text: Link to full Text with Trip Pro

33. Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015 Nursing Open. 2018;5:131–138. | 131 wileyonlinelibrary.com/journal/nop2 R ec eiv ed: 12 J anuary 2017 | A c c ep t ed: 5 D ec ember 2017 DOI: 10.1002/ nop2.121 RESEARCH ARTICLE Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting (...) , S hitsuka w a, T oon, E hime, Japan. Funding information T his r esear ch w as partially support ed b y JSPS KAKENHI G r an t N umber , 24390126 Abstract Aim : Postpartum depression is a mood disorder that commonl y affects wom en during the early postpartum period. The objective of this study was to analyse the association of postpartum depression with drugs (including contraceptive devices and implants) with spontaneou sly reported adverse events reported in the US Food and Drug Administration

Nursing open2018 Full Text: Link to full Text with Trip Pro

34. Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial.

Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial. Importance: Transcatheter aortic valve replacement (TAVR) is established for selected patients with severe aortic stenosis. However, limitations such as suboptimal deployment, conduction disturbances, and paravalvular leak occur. Objective: To evaluate if a mechanically

JAMA2018 Full Text: Link to full Text with Trip Pro

35. Estimating risk of adverse cardiac event after vascular surgery using currently available online calculators

Estimating risk of adverse cardiac event after vascular surgery using currently available online calculators 29066242 2017 12 22 1097-6809 67 1 2018 Jan Journal of vascular surgery J. Vasc. Surg. Estimating risk of adverse cardiac event after vascular surgery using currently available online calculators. 272-278 S0741-5214(17)31897-9 10.1016/j.jvs.2017.06.105 The decision to proceed with vascular surgical interventions requires evaluation of cardiac risk. Recently, several online risk (...) , ventricular fibrillation, primary cardiac arrest, and complete heart block; and (3) the Vascular Study Group of New England (VSGNE) Cardiac Risk Index estimates risk of postoperative MI only. Observed adverse cardiac events (ACEs) were compared with expected values for each calculator using a χ2 goodness-of-fit test. Institutional Review Board exemption was obtained. A total of 856 cases were included: 350 CEAs, 210 infrainguinal bypasses, 77 open AAA repairs, and 219 EVARs. For CEA, no risk calculator

EvidenceUpdates2018

36. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification

Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification WHO IRIS: Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification Browse Related links Files in This Item: File Description Size Format 1.91 MB Adobe PDF Title: Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification Authors: Issue Date: 2018 Edition (...) : 2nd ed Publisher: World Health Organization Place of publication: Geneva Language: English Description: ix, 48 p. Subject: Context: adverse effects URI: ISBN: 9789241513654 License: CC BY-NC-SA 3.0 IGO License URL: Appears in Collections: Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated. |

WHO2018

37. Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections.

Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections. Importance: Acute respiratory tract infections account for the majority of antibiotic exposure in children, and broad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing. It is not clear whether broad-spectrum treatment is associated with improved outcomes compared with narrow-spectrum treatment (...) pediatric primary care practices in Pennsylvania and New Jersey. Stratified and propensity score-matched analyses to account for confounding by clinician and by patient-level characteristics, respectively, were implemented for both cohorts. Exposures: Broad-spectrum antibiotics vs narrow-spectrum antibiotics. Main Outcomes and Measures: In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis. In the prospective cohort, the primary outcomes were

JAMA2017 Full Text: Link to full Text with Trip Pro

38. Adverse Drug Event Discovery Using Biomedical Literature: A Big Data Neural Network Adventure

Adverse Drug Event Discovery Using Biomedical Literature: A Big Data Neural Network Adventure 1 Appendix A A.1 How we select the relevant documents For scientific journals, we combine three journal ranking indices: (1) Impact Factor [11-12], (2) Eigenfactor [13-14], and (3) SJR (Scientific Journal Ranking) [15-16]. The scoring function below is employed to calculate the score of each article. Score (articles) = Impact Factor (journal) + Eigenfactor (journal) + SJR (journal) (1) Each individual (...) gabapentin-treated patients withdrew 2 from the study due to adverse events which included dizziness, abdominal pain, body odor, headache, diarrhea, abnormal thinking, nausea, and confusion”. Examples of No-ADEs sentences include: “Based on the different course of disease, many terms have been used to describe sclerosing mesenteritis, including mesenteric lipodystrophia, retractile or liposclerotic mesenteritis, mesenteric Weber-Christian disease, and xantogranulomatous mesenteritis”, and “Statins are a

JMIR medical informatics2017 Full Text: Link to full Text with Trip Pro

39. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data 29186504 2017 11 29 1522-9645 2017 Nov 27 European heart journal Eur. Heart J. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. 10.1093/eurheartj/ehx661 (...) Despite patient reports of neurocognitive disorders with lipid-lowering treatments (LLTs), large clinical trials have found no significant association between neurocognitive disorders and LLTs. We assessed incidence of neurocognitive treatment-emergent adverse events (TEAEs) from 14 Phase 2 and 3 trials of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab. Patients (most on background maximally tolerated statin) received alirocumab 75/150 mg every 2 weeks (n = 3340; 4029

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

40. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation

Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation 29111209 2017 11 27 2017 11 28 1879-1913 120 12 2017 Dec 15 The American journal of cardiology Am. J. Cardiol. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. 2176-2181 S0002-9149(17)31459-5 10.1016/j.amjcard.2017.09.003 We investigated the incidence of nonembolic adverse events in 2 cohorts of patients (...) with atrial fibrillation (AF) and validated the 2MACE score ([metabolic syndrome, age ≥75] [doubled]; [myocardial infarction or revascularization, congestive heart failure {HF}, and stroke, transient ischemic attack or thromboembolism]) as predictor of major adverse cardiovascular events (MACEs). We recruited 2,630 patients with AF from 2 different cohorts (Murcia AF and FANTASIIA). The 2MACE score was calculated, and during a median of 7.2 years (Murcia AF cohort) and 1.01 years (FANTASIIA) of follow-up, we recorded

EvidenceUpdates2017